2036. Plasma (1→3)-β-D-Glucan Levels correlate with Neurocognitive Functioning in HIV infected Adults
Session: Poster Abstract Session: Diagnostics: Mycology
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • IDSA BDG Poster final.pdf (593.2 kB)
  • Background: Although antiretroviral therapy (ART) has improved survival and morbidity, HIV-infected adults still have higher rates of non-AIDS disorders, such as neurocognitive impairment, than HIV-uninfected adults. (1-3)-b-D-glucan (BDG) is a fungal cell wall component which serves as a plasma biomarker for fungal infection and – in the absence of fungal infections – for gut barrier integrity failure and microbial translocation. The objective of this study was to determine whether higher plasma and cerebrospinal fluid (CSF) levels of BDG are associated with neurocognitive impairment [evaluated by global deficit score (GDS)] in HIV-infected adults.


    Methods:
    We measured levels of BDG in paired plasma and CSF samples, and compared levels with GDS, soluble urokinase plasminogen activator receptor (suPAR; a marker of monocyte activation and chronic inflammation that has previously been associated with non-AIDS disorders) and plasma CD4/CD8 ratio in a cohort of 61 HIV+ adults on suppressive ART. Study samples were collected as part of the prospective CHARTER study between 2005-2015 at the University of California San Diego and were stored at -80°C on the day of collection. BDG testing of blood plasma and CSF supernatant was performed at the Associates of Cape Cod, Inc., research laboratories using the Fungitell assay.


    Results:
    Median plasma BDG level was 18 pg/mL (range: 2-60 pg/mL), median CSF BDG level was 20 pg/mL (range: 0-830 pg/mL). Higher levels of plasma BDG were associated with more severe cognitive impairment as measured by the GDS (Spearman r=0.35; p=0.006, Figure). Individuals with neurocognitive impairment (i.e., GDS>0.5, n=33) had higher plasma BDG levels compared to unimpaired individuals (p=0.027). Plasma levels of BDG and suPAR correlated significantly (r=0.31, p=0.016), while all other correlations were non-significant [e.g., CSF BDG and GDS (r=0.23), plasma suPAR and GDS (r=0.19), CSF suPAR and GDS (r=-0.022), CD4/CD8 ratio and GDS (r=-0.028)]. 


    Conclusion:
    Elevated plasma levels of BDG may be an indicator of gut barrier integrity failure and an independent biomarker associated with neurocognitive functioning in HIV+ adults on suppressive ART.

    Martin Hoenigl, MD1, Scott Letendre, MD2, Malcolm Finkelman, MD3 and Sara Gianella, MD1, (1)University of California San Diego, San Diego, CA, (2)Medicine, University of California San Diego, La Jolla, CA, (3)Associates of Cape Cod, Inc, Falmouth, MA

    Disclosures:

    M. Hoenigl, None

    S. Letendre, None

    M. Finkelman, Associated of Cape Cod: Employee , Salary .

    S. Gianella, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.